Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
- PMID: 40697511
- PMCID: PMC12277822
- DOI: 10.1016/j.cpt.2024.12.002
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
Abstract
This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. MBD, a prevalent and debilitating complication of multiple myeloma, leads to bone pain, fractures, and skeletal-related events (SREs), which profoundly impact patients' quality of life. The guidelines offer a thorough framework for diagnosis, treatment, and continual assessment, emphasizing early detection and consistent monitoring using imaging techniques such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI). Treatment strategies prioritize the careful application of anti-myeloma agents, bisphosphonates, and denosumab to minimize bone loss and decrease SRE risk, complemented by surgical and radiotherapy interventions for structural or pain-related issues. Supportive care measures, including pain management, rehabilitation, nutritional support, and dental evaluations, play a crucial role in enhancing patient outcomes and preserving quality of life. This consensus advocates a standardized, evidence-based approach to managing MBD, ensuring comprehensive and coordinated care for patients.
Keywords: Bone disease; Diphosphonates; Multiple myeloma; Orthopedics; Quality of life; Recommendation; Therapeutic effect.
© 2024 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures



Similar articles
-
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2. Cochrane Database Syst Rev. 2020. PMID: 33270906 Free PMC article.
-
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22. Clin Orthop Relat Res. 2024. PMID: 38517402
-
Bisphosphonates for breast cancer.Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. PMID: 16034900 Updated.
-
Bisphosphonates and other bone agents for breast cancer.Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4. Cochrane Database Syst Rev. 2017. PMID: 29082518 Free PMC article.
-
Bisphosphonates and other bone agents for breast cancer.Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Oct 30;10:CD003474. doi: 10.1002/14651858.CD003474.pub4. PMID: 22336790 Updated.
Cited by
-
Microfluidic paper-based analytical extraction devices (µPAEDs): a cost-effective and portable solution for biomarkers, contaminants and VOC detection.Mikrochim Acta. 2025 Jul 5;192(8):482. doi: 10.1007/s00604-025-07333-4. Mikrochim Acta. 2025. PMID: 40616617 Free PMC article. Review.
References
-
- Jordan K., Proskorovsky I., Lewis P., et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22:417–426. doi: 10.1007/s00520-013-1991-4. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources